Anastasilakis AD, Papapoulos SE, Polyzos SA, et al. - Given that cessation of denosumab treatment is related to increases in bone turnover above baseline values and rapid bone loss, researchers conducted this prospective 2-year clinical trial to examine the effectiveness of zoledronate to prevent this bone loss in postmenopausal women with osteoporosis who were treated with denosumab (mean duration 2.2 years) and discontinued treatment after achieving osteopenia. Participants in the study were randomized to obtain a single zoledronate 5 mg infusion (n = 27) or two additional denosumab 60 mg injections (n = 30). According to findings, single intravenous zoledronate infusion given 6 months after the last denosumab injection prevents bone loss for at least 2 years, regardless of bone turnover rate. Follow-up is suggested as zoledronate therapy may not have the anticipated impact at 2 years in a few patients.